Guillain-Barré syndrome laboratory tests

Revision as of 17:05, 27 December 2018 by Fahimeh Shojaei (talk | contribs)
Jump to navigation Jump to search

Guillain-Barré syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Guillain-Barré syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Guillain-Barré syndrome laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Guillain-Barré syndrome laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Guillain-Barré syndrome laboratory tests

CDC on Guillain-Barré syndrome laboratory tests

Guillain-Barré syndrome laboratory tests in the news

Blogs on Guillain-Barré syndrome laboratory tests

Directions to Hospitals Treating Guillain-Barré syndrome

Risk calculators and risk factors for Guillain-Barré syndrome laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Laboratory findings consistent with the diagnosis of Guillain Barre syndrome include: Elevated CSF protein level, normal CSF WBC count, normal CSF cell count (in some cases there is mildly elevated cell count) and serum IgG antibody to GQ1b in Miller Fisher syndrome.

Laboratory Findings

References

  1. Yuki N, Hartung HP (June 2012). "Guillain-Barré syndrome". N. Engl. J. Med. 366 (24): 2294–304. doi:10.1056/NEJMra1114525. PMID 22694000.
  2. Nishimoto Y, Odaka M, Hirata K, Yuki N (March 2004). "Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination". J. Neuroimmunol. 148 (1–2): 200–5. doi:10.1016/j.jneuroim.2003.11.017. PMID 14975602.
  3. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (January 2014). "Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria". Brain. 137 (Pt 1): 33–43. doi:10.1093/brain/awt285. PMID 24163275.
  4. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I (October 1993). "Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies". Neurology. 43 (10): 1911–7. PMID 8413947.

Template:WH Template:WS